TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1543816

Group type: EXPERIMENTAL
Intervention: beta-galactosidase from Aspergillus niger added to intact milk
Number of subjects: 16
Study: 3717533

Group type: EXPERIMENTAL
Intervention: Treadmill exercise challenge tests (standardized protocol)
Number of subjects: 58
Study: 31327162

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30093522

Group type: EXPERIMENTAL
Intervention: Initial evaluation by a physical therapist (PT) integrated into primary care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual evaluation by a primary care provider (PCP)
Number of subjects: 0
Study: 27876689

Group type: EXPERIMENTAL
Intervention: SESAMe software (Web-based app for scheduling and monitoring emails)
Number of subjects: 270
Study: 24276460

Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg once weekly
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23656642

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions
Number of subjects: 600

Group type: COMPARATOR
Intervention: No prophylactic platelet transfusions
Number of subjects: 600
Study: 19900820

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1beta (IL-1beta) concentration in HbSS-NS (n=13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1beta (IL-1beta) concentration in HbSS-S (n=13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HbSS steady-state controls (n=7)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HbAA controls (n=6)
Number of subjects: 39
Study: 18097230

Group type: EXPERIMENTAL
Intervention: efavirenz, zidovudine plus lamivudine
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: efavirenz plus indinavir
Number of subjects: 1266

Group type: COMPARATOR
Intervention: indinavir, zidovudine plus lamivudine
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: efavirenz, zidovudine plus lamivudine and indinavir, zidovudine, lamivudine
Number of subjects: 1266
Study: 19158582

Group type: EXPERIMENTAL
Intervention: Automatic hospital order referral
Number of subjects: 184

Group type: COMPARATOR
Intervention: Screening ineligibility due to provider-oriented reasons
Number of subjects: 184

Group type: COMPARATOR
Intervention: Screening ineligibility due to patient-oriented factors
Number of subjects: 184

Group type: COMPARATOR
Intervention: Screening ineligibility linked to study protocol
Number of subjects: 184

Group type: COMPARATOR
Intervention: Study nonparticipation of those eligible
Number of subjects: 184
Study: 15688961

Group type: EXPERIMENTAL
Intervention: Toothbrush with antimicrobial additive (Microban)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Toothbrush without antimicrobial agent (control)
Number of subjects: 20
Study: 11819790

Group type: EXPERIMENTAL
Intervention: supplemented diet with glutamine, arginine and omega‐3‐fatty acids
Number of subjects: 48

Group type: COMPARATOR
Intervention: standard diet
Number of subjects: 48
Study: 9567620

Group type: EXPERIMENTAL
Intervention: Rokitamycin 800 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rokitamycin 1200 mg/day
Number of subjects: 20
Study: 7947364

Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nitrendipine (10 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Doxazosin and Nitrendipine
Number of subjects: 26
Study: 3360340

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection to the antagonist, nonparalytic horizontal rectus muscle
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no botulinum toxin treatment)
Number of subjects: 43
Study: 31958877

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (COCP) containing 20 mcg ethinyl estradiol/150 mg desogestrel for two continuous cycles
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAID); mefenamic acid 500 mg TDS for 5 days, 21 days apart for two cycles
Number of subjects: 84
Study: 31002478

Group type: EXPERIMENTAL
Intervention: 9-hour time-restricted feeding early (TRFe)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 9-hour time-restricted feeding delayed (TRFd)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 9-hour time-restricted feeding (TRF)
Number of subjects: 15
Study: 27871076

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 1 week pre-URS
Number of subjects: 165
Study: 25637076

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 25632646

Group type: EXPERIMENTAL
Intervention: Oral ivermectin 200 sg/kg body weight
Number of subjects: 148

Group type: COMPARATOR
Intervention: Topical lindane lotion 1% (two applications with a 1-week interval)
Number of subjects: 148
Study: 21511828

Group type: EXPERIMENTAL
Intervention: Pirfenidone 1200 mg/d
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2400 mg/d
Number of subjects: 77
Study: 19643495

Group type: EXPERIMENTAL
Intervention: 0.3 mg intravitreal ranibizumab
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal ranibizumab
Number of subjects: 4300
Study: 17370044

Group type: EXPERIMENTAL
Intervention: Carers with low mood
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Discrepant views about illness consequences
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Discrepant views on controllability
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Illness perceptions
Number of subjects: 82
Study: 15243609

Group type: EXPERIMENTAL
Intervention: Local haemostasis using oxidised regenerated cellulose after gauze packing for 3 minutes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no local haemostasis)
Number of subjects: 25
Study: 11376178

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Non-Hormone Replacement Therapy (non-HRT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 174
Study: 9338666

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 157

Group type: COMPARATOR
Intervention: Bare sclera excision
Number of subjects: 157
Study: 8177385

Group type: EXPERIMENTAL
Intervention: Hypothermic group (cooled to 32 to 33 degrees C within 6 hours of injury, n = 20)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normothermic group (n = 16)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypothermic group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normothermic group
Number of subjects: 36
Study: 3429382

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 0
Study: 31826235

Group type: EXPERIMENTAL
Intervention: BAT volume and 18F‐FDG uptake after personalized cold exposure
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: BAT volume and BAT 18F‐FDG uptake
Number of subjects: 102
Study: 29531100

Group type: EXPERIMENTAL
Intervention: Asthma APGAR tools
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1066
Study: 27016338

Group type: EXPERIMENTAL
Intervention: Systematic augmented feedback during spinal manipulation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Progressive withdrawal of augmented feedback during spinal manipulation training (Control group)
Number of subjects: 40
Study: 24814553

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 82
Study: 23098348

Group type: EXPERIMENTAL
Intervention: Awareness of causes of heart failure in hypertensive patients
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Awareness of left ventricular hypertrophy as a risk factor
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Awareness of major mechanisms of heart failure in hypertension
Number of subjects: 194
Study: 20533545

Group type: EXPERIMENTAL
Intervention: Abatacept (∼10 mg/kg of body weight)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 175
Study: 18793927

Group type: EXPERIMENTAL
Intervention: Single cone with quartz‐tungsten‐halogen (QTH) curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single cone with light‐emitting diode (LED) curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single cone with plasma‐arc curing (PAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single cone with chemical cure (uncured)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with quartz‐tungsten‐halogen (QTH) curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with light‐emitting diode (LED) curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with plasma‐arc curing (PAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction with chemical cure (uncured)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: System B + Obtura with quartz‐tungsten‐halogen (QTH) curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: System B + Obtura with light‐emitting diode (LED) curing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: System B + Obtura with plasma‐arc curing (PAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: System B + Obtura with chemical cure (uncured)
Number of subjects: 120
Study: 16459896

Group type: EXPERIMENTAL
Intervention: Classic lexical decision task (positive response for words)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modified lexical decision task (no response to words)
Number of subjects: 32
Study: 11953343

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9477021

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (scaling and rootplaning of all pockets in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation of all pockets with 1% chlorhexidine gel 3x in 10 min, rinsing 2x daily with 0.2% chlorhexidine, spraying tonsils with 0.2% chlorhexidine for 2 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (scaling and rootplaning per quadrant at 2-week intervals, oral hygiene instructions)
Number of subjects: 16
Study: 7627417

Group type: EXPERIMENTAL
Intervention: Skin protectant products (12 products evaluated)
Number of subjects: 0
Study: 2667780

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA) with sedation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 799557

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 28735449

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colloid bismuth subcitrate
Number of subjects: 0
Study: 27606616

Group type: EXPERIMENTAL
Intervention: Körpertambura treatment (10-minute session)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Active control group (Atemtherapie)
Number of subjects: 54
Study: 24955356

Group type: EXPERIMENTAL
Intervention: Scaffold enriched with autologous bone marrow stem cells (ABMC) (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fracture fixation alone (Group B)
Number of subjects: 30
Study: 22776216

Group type: EXPERIMENTAL
Intervention: TdaP vaccine
Number of subjects: 802

Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 802
Study: 20479425

Group type: COMPARATOR
Intervention: Cisplatin (CIS) 100 mg/m(2) on day 1 of weeks 1, 4, and 7
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Cisplatin (CIS) 75 mg/m(2) plus Tirapazamine (TPZ) 290 mg/m(2)/d on day 1 of weeks 1, 4, and 7 and TPZ alone 160 mg/m(2)/d on days 1, 3, and 5 of weeks 2 and 3 (TPZ/CIS)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Cisplatin (CIS)
Number of subjects: 861
Study: 18410547

Group type: EXPERIMENTAL
Intervention: LT4-LT3 combination therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: LT4 monotherapy
Number of subjects: 141
Study: 15634723

Group type: EXPERIMENTAL
Intervention: Oral vitamin-B and folic acid therapy (n = 27)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 12879814

Group type: EXPERIMENTAL
Intervention: Spiron (local formulation of risperidone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Risperdal (original formulation of risperidone)
Number of subjects: 12
Study: 11709253

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% applied 2 hours before surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no latanoprost)
Number of subjects: 64
Study: 9169310

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 8256322

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 105
Study: 3875450

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29358002

Group type: EXPERIMENTAL
Intervention: Natural food based tube feeding
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard tube feeding
Number of subjects: 118
Study: 28332859

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 mL) in 2 mL normal saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (4 mL)
Number of subjects: 100
Study: 27713626

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (95% of estimated VO2 max)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regular intensity exercise (85% of estimated VO2 max)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regular intensity exercise
Number of subjects: 31
Study: 23965288

Group type: EXPERIMENTAL
Intervention: Developmental Disability-Child Global Assessment Scale
Number of subjects: 30
Study: 22957434

Group type: EXPERIMENTAL
Intervention: Osmotic pump tablets with EC/PVP K30
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 0
Study: 20732978

Group type: EXPERIMENTAL
Intervention: Implementation of the Canadian CT Head Rule with active strategies including education, policy changes, and real-time reminders.
Number of subjects: 4531

Group type: COMPARATOR
Intervention: Control sites (no intervention).
Number of subjects: 4531
Study: 17564561

Group type: EXPERIMENTAL
Intervention: Cystatin-C
Number of subjects: 70

Group type: COMPARATOR
Intervention: Creatinine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cockcroft-Gault (C-G)
Number of subjects: 70

Group type: COMPARATOR
Intervention: MDRD
Number of subjects: 70
Study: 16211699

Group type: EXPERIMENTAL
Intervention: GERD diagnosis through endoscopy and symptoms assessment
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: Erosive esophagitis diagnosis through endoscopy
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: Symptomatic GERD diagnosis based on QUEST score
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: NERD diagnosis from symptomatic GERD
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: Predictive factors for erosive esophagitis
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: Predictive factor for GERD symptoms
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: Impact of traditional Japanese foods on GERD symptoms
Number of subjects: 2760
Study: 11489017

Group type: EXPERIMENTAL
Intervention: Mastery of Stress Instrument (MSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 0
Study: 9781832

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 39000

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 39000
Study: 7840507

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen 20 mg once daily for two years
Number of subjects: 128

Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 128
Study: 2849717

Group type: EXPERIMENTAL
Intervention: Acyclovir (500 mg/m² IV every 8 hours for 7 days, followed by 800 mg orally four times daily for 30 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (intravenous placebo for 7 days, followed by oral placebo for 30 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Acyclovir and Placebo
Number of subjects: 27
Study: 1498372

Group type: EXPERIMENTAL
Intervention: Topical khellin (2% solution in acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Number of subjects: 41
Study: 902597

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (3 X 5000 IU/24 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (3.6 g daily)
Number of subjects: 30
Study: 30324251

Group type: EXPERIMENTAL
Intervention: Neurodegenerative diseases
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Drug-induced movement disorders
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Functional movement disorders
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Structural brain lesions
Number of subjects: 96
Study: 28653221

Group type: EXPERIMENTAL
Intervention: Best practice alert intervention
Number of subjects: 12981

Group type: COMPARATOR
Intervention: Comparator (no alert)
Number of subjects: 12981
Study: 24911356

Group type: EXPERIMENTAL
Intervention: Jump-landing prevention program (3 months, coach-supervised)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study: 23369180

Group type: EXPERIMENTAL
Intervention: Task complexity (simple/complex)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-efficacy beliefs
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prior knowledge of English vocabulary
Number of subjects: 120
Study: 21844490

Group type: EXPERIMENTAL
Intervention: Telemonitoring and study physician medication management
Number of subjects: 296
Study: 19858751

Group type: EXPERIMENTAL
Intervention: Fast movements with accommodated resistance (FACC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lighter resistance and fast movement (Fast)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Heavy resistance/slow movement (Slow)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FACC
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Slow
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fast
Number of subjects: 48
Study: 17142931

Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study: 16225573

Group type: EXPERIMENTAL
Intervention: ESSURE
Number of subjects: 89

Group type: COMPARATOR
Intervention: Laparoscopic sterilisation
Number of subjects: 89
Study: 11426167

Group type: EXPERIMENTAL
Intervention: Radiofrequency medial branch neurotomy
Number of subjects: 60
Study: 9635648

Group type: EXPERIMENTAL
Intervention: Protocol group (DO2 > or =600 mL/min/m2)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (DO2 450 to 550 mL/min/m2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Age >75 yrs group
Number of subjects: 105
Study: 8071011

Group type: EXPERIMENTAL
Intervention: Factors affecting accrual performance in cancer control protocols
Number of subjects: 52
Study: 3341317

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (975 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31918406

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Sedentary behavior
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Sleep
Number of subjects: 430
Study: 30305153

Group type: EXPERIMENTAL
Intervention: DESCANT intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 360
Study: 28483653

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 119
Study: 25453582

Group type: EXPERIMENTAL
Intervention: EE/GSD patch
Number of subjects: 398

Group type: COMPARATOR
Intervention: EE/NGMN patch
Number of subjects: 398
Study: 23578862

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (45-50 vol%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia (1-1.4 vol%)
Number of subjects: 30
Study: 21798642

Group type: EXPERIMENTAL
Intervention: USB-PRP combination
Number of subjects: 10

Group type: COMPARATOR
Intervention: USB alone (control)
Number of subjects: 10
Study: 19125141

Group type: EXPERIMENTAL
Intervention: 15-minute interactive, computerized condom use intervention
Number of subjects: 430

Group type: COMPARATOR
Intervention: Comparison group (15-minute computerized multiple health risk assessment with no intervention)
Number of subjects: 430
Study: 16959690

Group type: EXPERIMENTAL
Intervention: Vivostat patient-derived fibrin sealant
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no additional hemostatic treatment)
Number of subjects: 80
Study: 14593457

Group type: EXPERIMENTAL
Intervention: nCPAP delivered by helmet
Number of subjects: 17

Group type: COMPARATOR
Intervention: nCPAP delivered by face mask (control)
Number of subjects: 17